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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a fatal, rapidly progressive neurodegenerative disease that
mainly affects the motor system. A number of potentially neuroprotective and neurorestorative disease-modifying
drugs are currently in clinical development. At present, the evaluation of a drug’s clinical efficacy in ALS is based on
the ALS Functional Rating Scale Revised, motor tests and survival. However, these endpoints are general, variable
and late-stage measures of the ALS disease process and thus require the long-term assessment of large cohorts.
Hence, there is a need for more sensitive radiological biomarkers. Various sequences for magnetic resonance
imaging (MRI) of the brain and spinal cord have may have value as surrogate biomarkers for use in future clinical
trials. Here, we review the MRI findings in ALS, their clinical correlations, and their limitations and potential role as
biomarkers.
Methods: The PubMed database was screened to identify studies using MRI in ALS. We included general MRI
studies with a control group and an ALS group and longitudinal studies even if a control group was lacking.
Results: A total of 116 studies were analysed with MRI data and clinical correlations. The most disease-sensitive MRI
patterns are in motor regions but the brain is more broadly affected.
Conclusion: Despite the existing MRI biomarkers, there is a need for large cohorts with long term MRI and clinical
follow-up. MRI assessment could be improved by standardized MRI protocols with multicentre studies.
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Background
Amyotrophic lateral sclerosis (ALS) is a neurodegenera-
tive disease that mainly affects the motor system. At
present, the only drug to have produced an increase in
patient survival in a controlled clinical trial is riluzole
[1]. The condition is always fatal; the median survival
time after onset is 36 [2], although there are great indi-
vidual variations [3]. Although ALS is a clinically
recognizable condition (in terms of the pattern of pro-
gressive upper and lower motor neuron degeneration),
the clinical presentation and progression are heteroge-
neous [4]. Moreover, there are now strong reasons for
considering a broader aetiological and pathogenic
spectrum [5]. This clinical heterogeneity is observed in
other neurodegenerative diseases, such as Parkinson’s
disease (PD). Nevertheless, it has been found that all PD
patients display degeneration and iron overload of the
substantia nigra, which might become a surrogate bio-
marker [6]. In ALS, iron overload in the motor cortex
was confirmed [7] after being suspected in mouse
models [8]. Ongoing drug trials in the field of neurode-
generative disease are mainly seeking to establish neuro-
protection and neurorestoration. Since neuroprotection
can never be unambiguously demonstrated in a given
patient, the concept of disease-modifying drugs (with a
slowing of the disease progression) has arisen. At
present, the evaluation of a drug’s clinical efficacy in
ALS is based on the ALS Functional Rating Scale Re-
vised, motor tests, survival or a combination of these
measures (such as the Combined Assessment of Func-
tion and Survival (CAFS)) [9, 10]. However, these end-
points are general, variable and late-stage measures of
the ALS disease process and thus require the long-term
assessment of large cohorts. These assessments are risky
and expensive, which considerably limits the number of
trials being conducted. A sensitive surrogate biomarker
might help to (i) reduce the sample size in pilot studies,
(ii) better define the sample size required in Phase III
clinical trials (by comparison with clinical scales) and
(iii) define endophenotypes for separate assessment in
clinical trials.
Biomarkers are typically divided into “wet biomarkers”
and “dry biomarkers”. Wet biomarkers are biological sub-
stances that are measured in a body fluid (such as whole
blood, serum, plasma, saliva or cerebrospinal fluid (CSF)).
“Dry biomarkers” are based on functional scales, task per-
formance, electrophysiology or imaging. Magnetic reson-
ance imaging is a widely available and non-invasive
technique, which makes it an appropriate candidate for
biomarkers. Although early reports stated that ALS starts
in the spinal cord, the initial site of neurodegeneration has
not been unambiguously identified; disease may start in
the spinal cord, in the motor cortex or at both sites simul-
taneously [11, 12]. The development of radiological
biomarkers in ALS is facilitated by the hypothesis that the
pathological changes in ALS radiate out from the initial
spinal and brain areas in which the most severe upper and
lower motor neuron dysfunction respectively occur (from
symptom onset onwards) with variability in the predomin-
ance of upper and lower motor neuron dysfunction [13].
The neurodegeneration then progresses along the motor
neurons of the ventral horn of the spinal cord and into
the corresponding areas of the motor cortex [13]. Despite
this modelization, the pattern of onset and progression re-
mains complex [13]. Hence, MRI of the spinal cord should
be an early, sensitive marker of subtle degeneration-
related changes. However, MRI of the spinal cord is com-
plicated by a number of technical difficulties (relative to
MRI of the brain). Firstly, the magnetic field is in-
homogeneous because the spinal cord is close to
bone, soft tissues and air. Secondly, the spine has a
small cross-sectional dimension, which thus requires
high-resolution data acquisition. Thirdly, the spine is
subject to motion of the CSF [14] and physiological
motion due to breathing [15].
Many different MRI techniques and sequences – in-
cluding voxel-based morphometry (VBM), diffusion ten-
sor imaging (DTI), magnetic resonance spectroscopy
(MRS), iron-sensitive sequences (T2*, R2* and SWI) and
functional MRI (fMRI) - are available for studying ALS-
related changes in the brain or spinal cord. Hence, we
reviewed the correlations between MRI findings and
clinical scores in ALS, and sought to establish whether
particular sequences may have value as surrogate bio-
markers in this disease.
Methods
We searched the PubMed database with the following
keywords: “ALS AND MRI OR amyotrophic lateral scler-
osis AND magnetic resonance imaging”, “ALS AND VBM
OR amyotrophic lateral sclerosis AND magnetic reson-
ance imaging ”, “ALS AND MR spectroscopy OR amyo-
trophic lateral sclerosis AND magnetic resonance
spectroscopy”, “amyotrophic lateral sclerosis AND diffu-
sion tensor imaging OR ALS AND DTI”, “amyotrophic
lateral sclerosis AND functional magnetic resonance im-
aging OR ALS AND fMRI”. There was no limitation on
the publication date but only publications in French or
English were considered. We included (i) general MRI
studies with a control group and an ALS group and (ii)
longitudinal follow-up studies (even if a control group was
lacking). We excluded therapeutic trials articles, reviews,
studies focused only on particular subgroups of ALS
patients such as cognitive impairment, genetic mutations.
Results
A total of 1336 articles were identified using database
searching, 651 were recorded after duplicates removal.
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405 were excluded (not ALS, not MRI or, therapeutic
clinical trials, not English or French, reviews) and 130
articles were finally excluded (studies focused only on
particulars subgroups of patients, other MRI sequences
or lacking of a control group). We analysed 116 articles.
Brain imaging
Structural magnetic resonance imaging (Table 1)
Three methods based on a three-dimensional, T1-
weighted sequence have been applied to ALS: VBM, vol-
ume analysis and the measurement of cortical thickness.
As a volume-based analysis, VBM involves the automatic
segmentation of grey matter and inter-subject compari-
son of the local grey matter density [16, 17]. After all the
data have been transformed in the same stereotaxic
space, the images are partitioned and corrected for the
separation between white matter, grey matter and CSF
as a function of voxel intensity [17]. Measurement of
cortical thickness is a surface-based technique analysis
in which the white matter and pial surfaces are automat-
ically extracted by applying image analysis packages such
as Freesurfer (http://surfer.nmr.mgh.harvard.edu/).
Most of these techniques have evidenced atrophy in the
precentral gyri [18–32]. However, some DTI studies used
VBM to show that ALS vs. control differences in the frac-
tional anisotropy (FA) of the precentral gyri were not due
to atrophy [33, 34]. In other studies, cortical atrophy was
not limited to the precentral gyri but extended to other re-
gions of the frontal lobe [18–24, 26–28, 32, 35] - especially
in apathetic patients with involvement of the cingulate
cortex [27, 36]. Other regions involved include several
parts of the temporal cortex [19–24, 32, 35], the hippo-
campus [24, 37–39], the parietal cortex (mostly in the
post-central cortex [18, 21, 23, 28]) and the insula [24].
Occipital grey matter atrophy [19, 20, 24, 35] and cerebel-
lar atrophy were less common [24]. When considering the
basal ganglia, a low volume of the thalamus [22, 24, 37]
and the caudate nucleus [37] have been observed. Few
studies have evidenced a relative reduction in the volume
of white matter (mainly in the frontal and temporal lobes)
[23]. There were no marked differences in the corpus cal-
losum [40]. Whole-brain analyses have evidenced low vol-
umes in the neocortex, grey matter, white matter [28] and
brain parenchyma [28, 32]. A longitudinal study showed
(i) a volume reduction in the left subiculum, the right
hippocampal area CA4 and the right dentatus gyrus and
(ii) an enlargement of the ventricles in 39 of the 112 ALS
patients [38].
Clinical correlations Specific MRI abnormalities have
been correlated with clinical scores, the disease stage (as
estimated with the original or revised ALS Functional
Rating Scale (ALSFRS and ALSFRS-R, respectively), the
speed of disease progression (i.e. the change in ALSFRS
or ALSFRS-R score, divided by the disease duration or
the time interval between two clinical assessments), the
disease duration and the survival time. Lower ALSFRS
or ALSFRS-R scores were associated with larger ventri-
cles and greater volume loss in the basal ganglia [38],
and volume changes in several parts of the frontal lobe
(such as Brodman area 10) [18]. In another study, a
higher ALSFRS-R progression rate was associated with
MRI changes in the left sensorimotor area; cortical
thickness was lower in patients with predominantly
upper motor neuron impairment (especially in the pre-
central gyrus and the left paracentral lobule), whereas
patients with predominantly lower motor neuron im-
pairment showed less difference relative to controls [20].
Grey matter density was lower in the cingulate and right
inferior frontal gyrus in patients with impaired emo-
tional empathy [36]. Poor survival in ALS is correlated
with volume loss in the basal ganglia and limbic struc-
tures [38]. The initial side of limb weakness in ALS
patients was not correlated with contralateral brain cor-
tical loss of volume [27]. Although atrophy was predom-
inant in the left sensorimotor cortex [27, 28], it was not
related to the side of onset [27]. A subgroup analysis (by
side of onset) found more widespread atrophy in the
contralateral brain cortex than in the group of ALS pa-
tients as a whole [28]. Precentral cortical thickness was
lower in patients with upper motor neuron clinical
features than in those with lower motor neuron clinical
features and in the ALS group as a whole [29].
In a study with a post mortem T1 sequence and histo-
logical assessment, an abnormally small difference in in-
tensity between cortical grey matter and subcortical
white matter was observed not only in the motor cortex
(including the precentral gyrus, supplemental motor area
and premotor cortex) but also in somatosensory areas
and the primary visual cortex. These signal abnormalities
were linked to neuron loss and an elevated number of
astrocytes [41].
Diffusion tensor imaging (Table 2)
DTI (also known as magnetic resonance tractography) is
based on the random diffusion (Brownian motion) of
molecules. In a spherical volume, the diffusion of water
has no main direction and its diffusion in the three di-
rections (λ1, λ2 and λ3) is equally likely. However, this is
no longer the case in an ellipsoid or cylindrical volume
and the diffusion is anisotropic. λ1 is the volume’s main
axis (axial diffusivity, AD) and λ2 and λ3 are the minor
axes (radial diffusivity, RD). By analysing the diffusion of
water in three directions, four parameters can be de-
fined: FA, RD, AD and mean diffusivity (MD, which is
the average of diffusion in the λ1, λ2 and λ3 axis, also
referred to as the apparent diffusion coefficient (ADC)).
The first three parameters describe the spatial variation
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Table 1 The main results of volumetric studies
Publication Numbers of
patients/controls
Main results Main clinical correlations
Abdulla et al.,
[39, 80]
58/29 Low volume in the right hippocampus Verbal memory test performance is correlated
with the left hippocampal volume.
Agosta et al.,
[21]
25/18 GM volume reduction in right precentral, left
inferior frontal cortex and temporal superior cortex.
Negative with ALSFRS-R and DD.
Agosta et al.,
[35]
44/26 Reduction in cortical thickness in the precentral,
frontal, limbic, parietal, temporal and occipital lobes.
DPR is correlated with the mean cortical thickeness
of left sensorimotor cortex.
Bede et al.,
[37]
39/44 GM volume reduction in the thalamus, caudate




23/24 GM volume reduction in the precentral, right
opercular and angular cortex, WM volume reduction
in the frontal lobe (especially the subcortical




14/20 Low GM density in the anterior cingulate and




20 (10 ALS and
10 ALS-FTD)/22
GM volume reduction in the precentral, frontal and









30/17 GM volume reduction in the left precentral cortex,
left frontal gyrus, medial frontal gyri and anterior
cingulate gyri.
Increased GM volume reduction in the dominant
(left) motor cortex irrespective to the side of limb
onset. Asymmetric GM reduction of the left
somatosensory cortex and the temporal gyri in
in right limb onset ALS
Ellis et al., [26] 16 (8 bulbar onset
and 8 limb onset)/8
GM volume reduction in the superior, middle and
medial frontal cortex. WM volume reduction in the
right frontal cortex.
Compared to limb onset ALS, bulbar onset ALS
showed GM volume reduction in the brainstem, the
cerebellum and in the fusiform gyri (BA 34) and WM
volume reduction along the left corticospinal tract.
Grosskreutz et al.,
[18]
17/17 GM volume reduction in the precentral, frontal
and parietal cortex. No WM atrophy.
ALSFRS-R correlated positively with GM volume
reduction in the right medial frontal gyrus (BA 10).
Kassubek et al.,
[32]
22/22 GM volume reduction in the right primary motor
cortex and the left medial gyrus and bilateral
inferior temporal gyrus.
Negative with ALSFRS-R and DD.
Meadcroft et al.,
2014
8/6 Post mortem study; loss of signal difference










29/20 GM volume reduction in the precentral, frontal,
right temporal and right occipital cortex.
Different patterns of volume reduction in ALS
group, high UMN burden, spinal onset and
faster progression compared to controls.
Sach et al., [33] 15/12 No difference -study not designed to voxel-based
morphometry.
Not available.









Correlations between the site of onset and upper
vs. lower motor neuron involvement, with focal
reductions in cortical thickness in the precentral
cortex.
Different patterns of volume reduction in ALS
subgroups: bulbar and spinal UMN signs, only
spinal UMN signs, classical ALS, UMN ALS-variants,
LMN ALS-variants or sites of onset compared to
controls. GM reduction is most important in the
left precentral cortex in bulbar onset vs. limb onset.
No correlations of MRI with DPR, DD and ALSFRS-R.
Thivard et al.,
[24]
15/25 GM volume reduction in the precentral, frontal
and temporal cortex (especially the hippocampus),
the parietal and occipital cortex, the thalamus and




12/12 GM reduction in the right and left precentral cortex. Not available.
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of water movement and are related to the orientation of
the studied structures. In contrast, MD corresponds to
the mean displacement of the water molecules within
the volume. The main application of DTI is the analysis
of the anatomical bundles that compose the white mat-
ter of the brain and the spinal cord [42–44]. Whereas
DTI corresponds to the analysis of the above-mentioned
parameters in a defined volume, tractography corre-
sponds to the analysis of a complete white matter tract.
Fractional anisotropy in ALS Low FA along entire cor-
ticospinal tracts (CSTs) is the most common observation
in patients with ALS [34, 45–58]. However, some studies
have only reported low FA in one or several parts of a
CST: the subcortical white matter of the precentral gyrus
[23, 24, 30, 33, 59–65], the corona radiata [24, 60–62,
66–68], the posterior limb of the internal capsule (PLIC)
[24, 33, 60, 62, 63], the cerebral peduncles [21, 59, 61]
and the pons [61]. Lastly, only one study failed to ob-
serve a difference in FA along a CST in ALS patients by
region of interest approach whereas tract based spatial
statistics (TBSS) showed decreased FA in corona radiate
and corpus callosum [68].
Low FA has also been observed in other regions: the
frontal lobe (excluding the CST) [21, 24, 33, 34, 45, 52, 56,
57, 61, 64], the cingulum [60], the corpus callosum [21,
33, 45, 50, 52, 58, 61, 67–69], the parietal lobe [24, 34, 45],
the temporal lobe [21], parahippocampal areas [61], the
hippocampus [34], the insula [34, 52], the cerebellum [61]
and the thalamus [24, 33, 53]. In a whole-brain compari-
son, many other small areas of ALS-modified white matter
tracts were observed [70].
A tractography study revealed that the CST volumes of
ALS patients are lower than in controls [71]. A DTI study
using a tract of interest-based fibre tracking found that
the radiological results mirrored the neuropathological
staging system [72], suggesting that the disease process ex-
tended in the following sequence: the corticospinal tract
(stage 1), the corticorubral and corticopontine tracts
(stage 2), the corticostriatal tract (stage 3) and the prox-
imal portion of the perforant pathway (stage 4) [73]. The
researchers suggested that this MRI-based staging system
could be used as a surrogate marker of disease progression
in clinical studies of ALS.
Diffusivity in ALS The most common observation in
patients with ALS is a relative increase in MD, reflecting
changes in white matter tracts. The MD was elevated
along entire CSTs [51, 53, 69] and in parts of CSTs, in-
cluding subcortical white matter in the precentral gyrus
[23, 34, 58, 60, 61], the corona radiata [34, 60], the PLIC
[23, 34, 60, 74], the cerebral peduncles and the pons
[34]. Diffusivity was also elevated in several parts of the
frontal lobe [23, 24, 52, 58, 60, 61], the temporal lobe
[23, 24, 52, 61], the hippocampal region [24, 34, 52],
the parahippocampal region [60], the parietal lobe
[23, 58, 61], the insula [23, 24, 52], the cingulum [53,
60], the occipital lobe [23], the cerebellum [23, 60]
(especially in C9ORF72-positive patients) [75], the
corpus callosum [23, 52, 60, 69] and the thalamus [53].
Conversely, two studies did not detect any differences in
diffusivity in ALS patients vs. controls [21, 63].
Radial and axial diffusivity in ALS Several studies have
found elevated RD and AD values in the right CST, the
right cingulum and the left anterior thalamic radiations
(on the basis of changes in FA or MD) [53]. In the PLIC,
AD is low [63] and RD is elevated [67] - especially in pa-
tients presenting with T2 hyperintensities in CSTs [63].
RD is elevated in white matter connected to the primary
motor cortex, the premotor cortex [56] and the corpus
Table 1 The main results of volumetric studies (Continued)
Walhout et al.,
[29]
153 (112 ALS, 19
UMN, 19 LMN)/60
GM reduction in the right and (predominantly) left
precentral cortex and the right paracentral cortex.
Bulbar and arms ALSFRS-R subscores are correlated
with cortical thickness of corresponding precentral
cortex areas of the motor homunculus. DPR is
correlated with the thickness of the right inferior




112/60 GM volume reduction in the hippocampus and
left subiculum.
Larger ventricles are correlated to a lower ALSFRS-R
score. Smaller basal ganglia, smaller limbic structures
and larger ventricles are associated with shorter
survival.
Zhang et al., [28] 43/43 GM reduction in the left precentral cortex, left
supplemental area and left postcentral gyrus.
Reduction in neocortex volume, GM and WM
volume and brain parenchymal fraction.
GM volume reduction is most important in the motor
cortex of the contralateral hemisphere of the limb of
onset. ALSFRS is positively correlated with GM density
in the left postcentral cortex and DPR is negatively
correlated with GM density in the right precentral cortex
Zhu et al.,
[31, 87]
22/22 GM reduction in the right and left precentral cortex. Negative with DD, DPR and all other clinical
parameters.
GM grey matter, WM white matter, BA Brodman area, DD disease duration, DPR Disease progression rate, UMN upper motor neuron
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Table 2 The main results of DTI studies
Publication Numbers of
patients/controls
Fractional anisotropy Mean diffusivity or apparent
diffusion coefficient
Radial and axial diffusivity Main clinical correlations
Abe et al., [64] 7/11 Low in parts of the right frontal
lobe and in the left subcortical
precentral area
Not available
Agosta et al., [21] 25/18 Low in parts of CSTs, the CC,
parts of the frontal lobe and
parts of the temporal lobe
No difference Negative
Bede et al., [75] 27/42 Low along CSTs, the CC,
cerebellum, brainstem, occipital
lobe and opercular and insular
regions
RD was low in the
cerebellum, brainstem,
occipital lobe and opercular
and insular regions
Not available
Canu et al., [23] 23/14 Low in subcortical parts of CSTs
and other parts of the frontal
lobe
Elevated in parts of the CSTs, left
postcentral gyrus, left insula, parts of the
left temporal lobe, right angular cortex,
parts of the frontal lobe, CC, parts of the
occipital lobe and parts of the cerebellum
Correlation between MD in bilateral
orbitofrontal region and DD
Chapman et al., [67] 21/21 Low in the CC, corona radiata
and PLIC
RD was low in the CC,
corona radiate and PLIC. AD
was elevated in the left
corona radiata and the
internal and external
capsules
Correlation between FA in parts of CC and
ALSFRS-R and negative correlation with DD,
correlation between RD in parts of CC and
DD
Ciccarelli et al., [45] 26/41 Low along CSTs, the CC, anterior
limb of the internal capsule,
external capsule, parts of frontal
lobe WM and postcentral gyri
Correlation between DPR and FA in left
cerebral peduncle, right PLIC, right corona
radiate right WM adjascent to the
precentral gyrus and CC
Ding et al., [74] 10/10 Elevated in the PLIC Not available
Ellis et al., [51] 22/20 Low along CSTs Elevated along CSTs Correlation between mean diffusivity in CST
and DD and between FA along CSTs and
ALS severity scale and spasticity scales.
Filippini et al., [56] 24/24 Low along CSTs and in the CC Elevated RD in WM linked
to the primary motor and
premotor cortex and the CC
Inverse correlation between FA and UMN
score along CSTs, correlation between FA
and ALSFRS-R and DD along CSTs
Foerster et al., [55] 29/30 Low along CSTs Correlation between FA and ALSFRS-R
along CSTs
Iwata et al., [49] 31/31 Low along CSTs Negative
Iwata et al., [50] 18/19 Low along CSTs and in the
motor part of the CC
Elevated along CSTs Correlation between DD and FA along
CSTs. Inverse correlation between FA in
CSTs and global and localized UMN
impairment score and between FA along
CST and UMN rapidity index.













Table 2 The main results of DTI studies (Continued)
Keil et al., [61] 24/24 Low in parts of CSTs,
supplementary motor area, CC,
parts of the frontal lobe and the
parahippocampal area
Elevated in motor areas, parts of CSTs, parts
of the frontal and temporal lobe, and the
postcentral gyrus
Correlation between FA along CSTs and
ALSFRS-R. Correlation between executives
functions (sfs36 score) and FA in cerebel-
lum. At 6 months, negative correlation be-
tween FA along CSTs and DD correlation
between FA along CSTs and frontal WM
and ALSFRS-R. Correlation between FA in
CST at brainstem level and executives func-
tions, negative correlation between ADC in
the cerebellum and parahippocampal gyri
and executives functions (sfs36)
Keller et al., [68] 33/30 Low in the corona radiata and
CC
Negative
Liu et al., 2014 19/13 Low along CSTs Correlation between FA along left CST and
ALSFRS-R
Menke et al., [77] 21/0 (follow-up
study)
Progressive reduction in the
PLIC
Correlation between FA at baseline and DPR
Metwalli et al., [69] 12/19 Low along CSTs, the CC Elevated along CSTs, the CC AD and RD were elevated
along CSTs, RD was
elevated in the CC, parts of
frontal and parietal lobe
Negative
Muller et al., 2011 19/19 Low in parts of CSTs, the
parahippocampal area, insula
and brainstem
Correlation between FA in parts of CSTs
and ALSFRS-R
Nickerson et al., [46] 2/0 (follow-up
study)
A linear reduction along CSTs
during one year follow-up
Not available
Poujois et al., [65] 19/21 Low in CSTs from the left
corona radiate to the precentral
gyrus and in both cerebral
peduncles
Muscular strength is lower on the right side
corresponding to the lower FA in the left
CST
Prell et al., [60] 17/17 Low in parts of CSTs and the
cingulate gyrus
Elevated parts of CSTs, parts of frontal lobe,
cingulate gyrus, parahippocampal region,
CC, cerebellum.
Correlation between FA in internal capsule
and contralateral strength of the lower limb.
Different patterns in FA and ADC of bulbar
and limb onset compared to controls.
Prudlo et al., [70] 22/21 Low throughout the CSTs, the
anterior limb of the internal
capsule, thalamic radiations, the
CC, association fibres and the
middle cerebellar peduncle
Correlation between FA in many voxels of a
whole DTI brain analyses with ALSFRS-R
Pyra et al., [59] 14/14 Low in left precentral gyrus Correlation between spasticity and ADC in
contralateral precentral gyrus
Rajagopalan et al., [63] 47/10 Low in the left subcortical motor
area and right PLIC
AD was low in the PLIC. RD
was elevated in the PLIC of
patients with T2














Table 2 The main results of DTI studies (Continued)
Rosskopf et al., [57] 100/93 Low along CSTs Correlation between FA along CSTs and
ALSFRS-R
Sach et al., [33] 15/12 Low in parts of CSTs, premotor
areas, CC and right thalamus
Low FA in patients without UMN signs in
parts of CST, CC and right thalamus. No
correlation available with clinical score
Sage et al., [34] 28/26 Low along CSTs and the right
postcentral gyrus
Elevated in parts of CSTs Correlation between FA and ALSFRS in
several parts of CSTs and in prefrontal lobe
Sage et al., [52] 28/26 Low in parts of CSTs, parts of
the frontal lobe, insula,
hippocampus, cerebral
peduncles and CC
Elevated along CSTs, hippocampus, insula,
parts of the temporal and frontal lobe and CC
Correlation between FA along CSTs, in
prefrontal area and ALSFRS. Negative
correlation between MD along CST,
hippocampus, cerebellum, parietal and
temporal lobe and ALSFRS.
Sarica et al., [53] 14/14 Low in right CSTs and left
anterior thalamic radiations
Elevated in right CSTs, cingulum and left
anterior thalamic radiations
RD elevated in right CSTs
and left anterior thalamic
radiations. AD elevated in
the right cingulum
Negative (p ≤ 0.05)
Schirimrigt et al., 2007 10/20 Low along CSTs (nb: study with
a technical objective)
Correlation between FA along CSTs and DD
Stagg et al., [47] 13/14 Low along CSTs Elevated along CSTs Negative
Tang et al., [58] 69/23 Low along CSTs, in frontal WM
and the genu of the CC
Elevated in the centrum semi-ovale and
frontal and parietal WM
Not available
Thivard et al., [24] 15/25 Low along CSTs, premotor
cortex, right thalamus, insula,
parts of parietal lobe
Elevated in the motor cortex, premotor
cortex, insula, hippocampus, and right
superior temporal gyrus
Correlation between FA along CST, insula,
premotor cortex, cingulum, precuneus, CC
and ALSFRS-R, negative correlation be-
tween FA in CC and centrum semiovale
and DD
Verstraete et al., [30] 12/12 Low in the rostral part of CSTs
and the CC
Not available
Wang et al., [71] 16/17 Low CST volume in DTI Negative
Yin et al., [48] 8/12 Low along CSTs Not available
Zhang et al., [62] 17/19 Low in parts of CSTs Elevated in parts of the CSTs Correlation between FA in right superior
CST and ALSFRS-R and motor subscore of
ALSFRS-R
FA fractional anisotropy, MD mean diffusivity, ADC apparent diffusion coefficient, RD radial diffusivity, AD axial diffusivity, CST corticospinal tract, PLIC posterior limb of the internal capsule, CC corpus callosum, DD













callosum [56, 67, 69]. Lastly, RD and AD are elevated in
the cerebellum of C9ORF72-positive patients [75].
Longitudinal studies In longitudinal analyses, low FA is
observed in the right superior CST [62], precentral sub-
cortical regions, mesencephalic CSTs and parts of cere-
bellum [61]. FA was found to fall in a progressive, linear
manner along the CSTs [34, 46, 76], and the diffusivity
of the external and internal capsule was elevated [61].
AD is elevated in CSTs [77]. However, a recent longitu-
dinal study found that white matter defects (as assessed
by DTI) progressed much slowly that in the grey matter
defects - notably in the basal ganglia [78].
Clinical correlations Many studies have found that dis-
ease progression (as defined by the change over time in
the ALSFRS or ALSFRS-R score) is correlated with the
changes in FA in CSTs [24, 34, 45, 61, 62, 77, 79]. Further-
more, the disease duration is correlated with FA in entire
CSTs or parts of CSTs [24, 50, 54, 56, 61, 77]. Conversely,
the disease duration was negatively correlated with FA in
the cerebellum [61], the subcortical white matter of insula,
the ventrolateral premotor cortex, the cingulum, the pre-
cuneus and the splenium of the corpus callosum [24].
Lower-limb muscle strength was correlated with the
contralateral FA in CSTs [60]. Diffusivity values in CSTs
and in the parietal lobe, temporal lobe and cerebel-
lum were also correlated with disease progression [52,
79]. Diffusivity in CSTs was correlated with disease
duration [79], and contralateral diffusivity in CSTs
was correlated with spasticity [59].
Whereas both limb-onset patients and bulbar-onset
patients differed from controls in terms of FA along
CSTs, the two patient groups had similar values [60].
The CSTs were more impaired in bulbar-onset patients
than in limb-onset patients when considering FA, MD
and RD but not AD [80]. Tractography revealed a large
number of differences between controls and patients de-
fined as definite/probable according to the El Escorial
criteria, whereas there were fewer differences between
controls and a possible/suspected group [79].
Neurophysiological correlations FA in CSTs was re-
lated to the central conduction time in a transcranial
magnetic stimulation study [33, 49] (Iwata et al., [49];
Sach et al., [33]).
Diagnostic accuracy An individual patient data meta-
analysis of CST studies concluded that DTI lacks suffi-
cient diagnostic discrimination [81]. The pooled sensitiv-
ity and specificity were only 0.68 and 0.73, respectively.
Researchers have also suggested that a multimodal ap-
proach (combining DTI with methods such as MRS)
may be more promising [55].
Magnetic resonance spectroscopy (Table 3)
MRS is a non-invasive means of assessing brain metab-
olism, based on the chemical properties of molecular
structures. Results are expressed as peaks. The main
brain metabolites monitored with MRS include N-
acetyl-aspartate (NAA), choline (Cho, a cell membrane
marker), creatine (Cr) and phosphocreatine (Pcr). The
Cr + Pcr peak is a marker of energy metabolism; the level
of Cr is assumed to be stable and is used to calculate the
metabolite ratio. At a field strength of 1.5 T, the peaks
for glutamine (Gln), glutamate (Glu, an excitatory
neurotransmitter) and gamma aminobutyric acid
(GABA, an inhibitory neurotransmitter) overlap to form
a complex referred to as “Glx”; higher field strengths are
required for more accurate quantification of this me-
tabolites. The simple sugar myo-inositol (Ins) is ab-
sent from neurons but present in glial cells. Hence,
elevated brain levels of Ins are associated with glial
proliferation, whereas low levels are associated with
glial destruction [82–84].
The main results for the CST concern the ratio between
the NAA peak on one hand and the Cho and Cr + Pcr
peaks on the other. In ALS patients, low levels of NAA
have been observed in the precentral corticosubcortical
region [85–91], in the PLIC [85] and in entire CSTs [55,
59, 86, 92]. Glu and Glu + Gln were found to be elevated
in the precentral corticosubcortical region and in the PLIC
[85], whereas Cho was found to be elevated in the precen-
tral region [88, 93, 94] and along the CSTs [47, 59, 92].
Levels of the inhibitory neurotransmitter GABA were low
in the precentral cortex [55, 95], and levels of Ins were
low in the precentral corticosubcortical region [89].
Whereas the above-mentioned studies used defined
voxels for MRS acquisition, whole-brain spectroscopy
has revealed low NAA/Cho or NAA/Cr ratios in many
other regions [93].
Follow-up studies have shown a decrease in the NAA
peak in the precentral cortex (with no differences for
other metabolites) [96], a decrease in the NAA/Cho peak
and an increase in the Cho/Cr peak [91].
Clinical correlations Patients with definite or probable
ALS (according to the El Escorial criteria) had low levels
of NAA and high levels of Ins and Cho in the precentral
cortex. In patients with possible or suspected ALS, only
Cho and (on the left side) Ins were elevated. In another
study of suspected ALS patients, only right-side Ins and
right-side Cho were elevated [79]. Low NAA and high
Cho and Ins levels are associated with clinical disease se-
verity [94]. Lower NAA levels in the precentral gyrus,
disease duration and disease progression were intercor-
related [59], and a low NAA/Cho ratio was associated
with poor survival [88].
Grolez et al. BMC Neurology  (2016) 16:155 Page 9 of 17
Diagnostic accuracy In a recent study, the combination
of MRS and DTI yielded a sensitivity of 0.93 and a specifi-
city of 0.85, whereas the DTI data alone gave values of
0.86 and 0.70, respectively [55]. A criterion combining the
MRS data, hypointensity in the precentral gyri and hyper-
intensity in the CSTs yielded a sensitivity of 0.78 and a
specificity of 0.82; when each of the three parameters was
considered alone, the sensitivity and specificity values did
not exceed 0.71 and 0.75, respectively [90].
Iron imaging
Iron overload appears to be involved in the physiopa-
thology of ALS [8, 97]. However, very few studies have
analysed the iron content in the brain of ALS patients. A
Table 3 main results of magnetic resonance spectroscopy studies
Publication Numbers of
patients/controls
Main results Main clinical correlations
Bowen et al., [94] 18/12 Cho and ins were elevated in the MC. NAA and Cr
were correlated in left MC
Correlation between ins in MC and UMN disability,
negative correlation between Naa in MC and UMN
disability, higher Cho in sever UMN disability group
Cervo et al., [90] 84/28 NAA/(Cho + Cr) was low in the MC Negative
Foerster et al., [95] 10/9 Low gamma aminobutyric acid in the MC but not in
WM
Negative
Foerster et al., [55] 29/30 NAA and gamma aminobutyric acid were low and
ins was elevated in the left MC
Negative correlation between gamma aminobutyric
acid in MC and DD, correlation between Naa peak in
MC and ALSFRS-R
Govind et al., [92] 38/70 NAA was low and Cho was elevated in most parts of
CST, and Cho/NAA was elevated in all parts of the
CSTs
Negative correlation between Cho/Naa in the left
entire CST and forced vital capacity, negative
correlation between Cho/Naa in the left CST and
right and left finger tap rate, negative correlation
between Cho/Naa in left MC and semiovale centrum
and right finger tape or forced vital capacity
Han et al., [85] 15/15 NAA/Cr peak was low in the MC and PLIC, Glu/Cr
and Glu + Gln/Cr peaks were low in the MC and
PLIC
Negative correlation between Glu + Gln/Cr with
Norris score
Kalra et al., [88, 89] 63/18 NAA/Cho and NAA/Cr was low in the MC, and Cho/
Cr was elevated in the MC
Relation between decreased Naa/Cho in the MC and
reduced survival.
Kalra et al., [88, 89] 17/15 NAA/Ins, NAA/Cr and NAA/Cho were low in the MC,
and Ins/Cr was elevated in the MC
Negative (p ≤ 0.05)
Liu et al., [87] 19/13 NAA/Cr was low in the MC Negative
Lombardo et al., [79] 32/19 NAA/Cr was low and ins/Cr and Cho/Cr were
elevated in the MC.
Abnormalities were correlated with the El Escorial
score
Pohl et al., [91] 70/48 NAA, Pcr + Cr, NAA/Cho and NAA/(Pcr + Cr) were
low in the MC. At 12 months, NAA/Cho was low and
Cho/(Pcr + Cr) was elevated
Not available
Pyra et al., [59] 14/14 NAA/Cho and NAA/Cr were low in the MC and
corona radiata, and Cho/Cr was elevated in the MC
Correlation between Naa/Cho peak in MC and DD,
negative correlation between Naa/Cho in MC and
corona radiata and DPR
Rooney et al., [86] 10/9 NAA/(Cho + Cr) was low in the MC and CST but not
in other regions
Correlation between Naa/(Cho + Cr) in the MC and
maximum finger tape rate
Stagg et al., [47] 13/14 NAA was low along the CSTs Correlation between Naa peak along CSTs and
ALSFRS-R
Unrath et al., [96] 8/0 Progressive decrease over time in the NAA peak
throughout the MC
Progressive decrease of Naa/(Cr + Cho) in the less
affected hemisphere. Correlation between Naa and
the more or less affected side (ALSFRS subscore).
Correlation between Naa/(Cr + Cho) and the less
affected side (ALSFRS subscore)
Verma et al., [93] 21/10 NAA/Cho was low in the right lingual gyrus, parts of
the occipital lobe, left supramarginal gyrus and left
caudate. NAA/Cr was low in the right MC, left frontal
inferior operculum, right cuneus, parts of the
occipital lobe, left caudate and left Heschl gyrus
Not available
MC motor cortex, CST corticospinal tract, PLIC posterior limb of the internal capsule, WM white matter, NAA N-acetylaspartate, Cho choline, Gln glutamine, Glu glu-
tamate, PCr phosphocreatine, Cr creatine or creatine + Pcr (the distinction is not relevant for interpretation), DD disease duration, DPR disease progression rate
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variety of techniques are available, including relaxometry
(T2, T2* or R2*) and the susceptibility-weighted imaging
[98, 99] (SWI, which is probably more sensitive than
relaxometry [100]). Multi-echo T2* and R2* sequences
are sensitive to magnetic field inhomogeneities. The
value of R2* is measured by voxel-by-voxel modelling of
the exponential decrease in signal [101, 102]. In post-
mortem studies, R2* values have been found to be corre-
lated with the iron content [103].
Susceptibility-weighted imaging and quantitative
susceptibility mapping (QSM)
SWI is derived from T2* sequences and can be described
as a flow-compensated, high-spatial-resolution T2*
weighted sequence. The main advantage over conven-
tional T2* sequence is better contrast [101]. QSM is
based on the analysis of phase information. The main
sources of phase shifts in biological tissues are the iron,
calcium, lipid and myelin contents [104]. The value of
QSM in ALS was confirmed in a post-mortem study, in
which the iron content of grey matter was assessed more
accurately than that of white matter [105].
The initial studies in the field noted a shorter T2 time in
the motor cortex of most ALS patients (vs. controls) [106],
although this was not confirmed a few years later [107].
Later studies found a correlation being T2* shortening and
iron deposition in the microglia of the motor cortex (ac-
cording to a post-mortem examination) [7, 106, 108]. Iron
overload in the motor cortex was also described in SWI
studies [109] and qualitative studies [100]; in the later study,
there were no differences between ALS patients and con-
trols in terms of T2 or T2*. A few quantitative studies have
looked at white matter or deep grey matter [109, 110].
There was a trend towards iron accumulation in CST white
matter in a relaxometry study [110]. Iron overload was also
present in the red nucleus, substantia nigra, globus pallidus,
putamen [109] and caudate nucleus [110]. The use of SWI
sequences revealed widespread iron overload and myelin
defects in the white matter of all brain lobes and corpus
callosum [111]. A retrospective study of iron deposition in
motor cortex found that quantitative susceptibility mapping
was more accurate than T2*, T2 or FLAIR sequences [112].
A follow-up study has highlighted the progression of a
T2 hypointense area in the motor cortex after 6 months,
which was strongly and negative correlated with the
ALSFRS score [108]. Lastly, changes in SWI sequences
in the corpus callosum are correlated with the ALSFRS-
R score [111].
Imaging of the spinal cord
The few studies to have analysed the spinal cord re-
vealed atrophy in the cervical and upper thoracic regions
[113–115]. A DTI study reported low FA, elevated RD
and a high magnetization transfer ratio in lateral
segments of the cervical spinal cord [114]. Atrophy of
the cervical and upper thoracic spinal cord progressed
over time, whereas the DTI changes were relatively
stable [115]. This observation agrees with the results of
a longitudinal brain MRI study showing that grey matter
defects (but not white matter defects) progressed over
time [78]. Sensory pathways were also involved, with
a decreased FA and an elevated MD and elevated RD
in the posterior part of the cervical spinal cord [115,
116]. MRS of the cervical spinal cord revealed low
NAA/Cr + Pcr and NAA/Ins peaks and an elevated
Ins/Cr peak [117].
Clinical correlations Cervical and upper thoracic spinal
cord atrophy was correlated with upper arm muscle
strength, as measured by manual testing [114]. FA in the
cervical spinal cord was correlated with the ALSFRS
score. The rate of atrophy in a follow-up study was cor-
related with the rates of changes of an arm ALSFRS-R
score and an arm strength score (in a manual test) [115].
The NAA/Cr + Pcr and NAA/Ins peaks were positively
correlated with the ALSFRS-R score and forced vital
capacity but negatively correlated with disease progres-
sion [117].
Functional MRI
Brain fMRI is a recent technique based on blood flow
and blood-oxygen-level dependent (BOLD) contrast,
which in turn are based on the neurovascular conse-
quences of neuronal activation [118]. The paramagnetic
properties of deoxyhaemoglobin lead to signal reduction
in gradient echo sequences [101]. Brain fMRI sequences
are acquired in the resting state or during performance
of a motor, auditory, cognitive, or visual task [119–121].
The resting state sequences are quite similar to T2* se-
quences [101].
In the resting state, functional connectivity is based on
fluctuations of the BOLD signal. In general, seven “de-
fault” networks can be identified: default mode, execu-
tive control, visual salience, sensorimotor, dorsal
attention and auditory networks [118, 122]. Functional
connectivity between specific brain regions and/or net-
works and the rest of the brain can then be analysed
[118]. Resting-state analysis can also provide information
about local activation (by analysing the amplitude of
low-frequency fluctuations (ALFF), for example).
The resting state Resting-state studies have evidenced
the widespread reorganization of functional connectivity
in ALS patients. This reorganization can be observed as
either elevated functional connectivity or low functional
connectivity. Functional connectivity was found to be
low in several parts of the frontal lobe (the right orbito-
frontal cortex, the left inferior frontal cortex [123] and
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especially the motor cortex [124]) but was elevated in
the parietal lobe (the left precuneus and the right angu-
lar gyrus [123]) and the left frontoparietal network [123].
This agrees with the elevated sensorimotor connectivity
of the left sensorimotor cortex with several regions of
the right hemisphere (mainly the cingulate cortex, para-
hippocampal gyrus and cerebellum crus II) [125]. When
compared with alterations of the CSTs (according to FA
measurements), there were also changes in right sensori-
motor connectivity; the connectivity was elevated if the
CST was normal in a DTI analysis but was low if the
CST was abnormal [125]. A network-by-network analysis
revealed low activity in the default mode network [126]
and elevated activity in the sensorimotor network (both of
which include parts of the frontal lobe [126, 127],
although not the same ones). Thalamic connectivity is also
elevated [127].
Resting-state activity (as measured by the ALFF)
was elevated in the frontal lobe (the left anterior cin-
gulate, right superior frontal cortex [31] left medial
frontal gyrus and right inferior frontal gyrus [128]),
the temporal lobe (the right parahippocampal cortex
and the left inferior temporal cortex) and the occipital
lobe (the middle occipital cortex) [31] but low in the
right fusiform gyrus, the visual cortex and right post-
central gyrus [128].
The resting-state connectivity in the frontal cortex is
correlated with disease progression and duration [128].
The connectivity between the left sensorimotor cortex
and the right parahippocampal gyri and fourth cerebellar
lobule is correlated with the ALSFRS-R [125]. Connect-
ivity of the dorsal part of the precentral gyri was corre-
lated with hand strength [124]. Activity in the right
parahippocampal gyri was correlated with disease pro-
gression, whereas activity in the left anterior cingulate
and left temporal gyrus was correlated with cognitive pa-
rameters [31].
Activation in fMRI In motor tasks, activation of the
motor cortex was elevated [129–131] and spread widely
across the supplementary motor area, the premotor cortex
[132] and the parietal somatosensory cortex [129, 132]. In-
hibition was low [130]. Activation of the ipsilateral sen-
sorimotor cortex was possibly linked to a compensatory
mechanism in ALS [133]. A visual task was associated
with poor activation of the secondary visual cortex and
strong activation of associative areas, whereas an auditory
task produced delayed activation in the secondary audi-
tory cortex, and somatosensory stimulation produced pro-
longed activation of the right inferior frontal gyrus and
right posterior insular cortex [134]. In a modified “go”/
“no-go” task, activation of the primary motor cortex, other
motor areas, the frontal lobe, the insula and the cerebel-
lum was found to decrease over a three-month period
[135]. Using another type of stimulus, activation of the
hippocampus also fell after 3 months [135]. In a theory-
of-mind task designed to evaluation the mirror neuron
system, ALS patients displayed abnormally strong activa-
tion of the right anterior cortical areas [136]. A link
between the severity of motor weakness and the pattern of
activation has never been observed, although the
ALSFRS-R score was correlated with the signal change in
the sensorimotor cortex in one study [129]. When consid-
ering the clinical phenotype, only a bulbar-onset subgroup
showed low activation of the motor cortex during tongue
movements [131]. Shifts in cerebellar or hippocampal acti-
vation were correlated with the ALSFRS-R score.
Discussion
When considering the data as a whole, the most disease-
sensitive MRI patterns are located in motor regions (and
especially along the CST from the cortex to the spinal
cord). However, ALS also affects the brain more broadly;
other parts of the frontal lobe, the temporal lobe, the
hippocampus, the parietal lobe, the cingulum and the in-
sula are commonly involved, whereas the occipital lobe
is less frequently involved. For most MRI parameters,
patient vs. control differences are mostly apparent in the
left (dominant) hemisphere. The various MRI patterns
appear to reflect disease severity, progression and dur-
ation. With fMRI, abnormally high levels of activation in
the motor cortex are probably related to the disease-
related loss of inhibition. Excessive activation appears to
be associated with compensation for the loss of function
caused by neuron loss.
Limitations of neuroimaging as a biomarker for ALS
The low average number of participants represents the
main limitation: very few published studies have featured
more than 30 subjects per group (i.e. ALS and control
groups). Together with the differences in the propor-
tions of the various patient phenotypes, this explains the
high variability of the results - particularly outside the
motor cortex and the CSTs [137].
Only a small proportion of morphometric studies in-
cluded a whole-brain analysis. The proportion is higher
for DTI studies and low (only one study) for MRS. The
selection of regions of interest may over-emphasize
changes in the CSTs and the motor system and under-
emphasize changes outside these areas.
Very few studies had a longitudinal design, which is
nevertheless required for the full interpretation of abnor-
malities. The main difficulty in setting up longitudinal
studies relates to the rapid disease progression and the
appearance of respiratory failure, which prevents pa-
tients from lying in the MRI for any length of time. In
studies longer than 6 months, the drop-out rate is usu-
ally over 50 %.
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fMRI studies have highlighted both elevated activity
and low activity in several parts of the brain. The main
physiopathological explanations relate to a physiological
compensation response or elevated activity due to the
loss of inhibitory mechanisms [127].
Spinal cord imaging is a rarely applied imaging mo-
dality in ALS, despite the pivotal involvement of the an-
terior horn of the spinal cord in ALS [137]. Spinal cord
imaging appears to be most commonly used in studies
of multiple sclerosis, since all studies in this disease con-
text found differences (relative to controls) in the cer-
vical spinal cord. To the best of our knowledge, no
studies of the whole spinal cord have been published –
perhaps as a result of technical obstacles.
The biomarker concept
Currently, the diagnosis of ALS is based on the revised
El Escorial criteria (also known as the Airlie House cri-
teria), which were established in 1998 and published in
2000 [138]. Although diagnosis during the course of the
disease has become relatively easy, the onset of ALS can
be masked by clinical overlap with many other diseases
[139]. The ideal biomarker is not only sensitive and spe-
cific (for various disease phenotypes) early in the disease
process but must also easy to access [140]. In ALS, the
typical time interval of 12 months between the initial
symptoms and disease diagnosis makes this challenge
tougher still [140–142]. The best way of determining
early biomarkers for ALS may be to monitor cohorts of
presymptomatic patients identified by genetic studies
[143]. Although wet biomarkers based on blood or CSF
analysis are relatively accessible, there are many candi-
dates and study-to-study reproducibility appears to be
quite low [5, 140].
Perspectives
There is currently a need for a robust clinical-radiological
description of ALS using MRI as a function of the disease
progression, the various endophenotypes and left/right
asymmetry (in terms of upper and lower motor neuron
impairment, bulbar involvement, and the cognitive profile
ranging from frontotemporal dementia, apathy and dysex-
ecutive syndrome to mild attention disorders).
Despite the few number of studies, spinal cord could be a
promising region of interest, although this approach is cur-
rently limited by technical post-processing difficulties and a
sizeable number of large scale and longitudinal studies in-
volving the spinal cord is needed to build stronger MRI bio-
markers of the spinal cord. It may be of value to combine
several techniques (e.g. atrophy mapping and measure-
ments of the iron content in the grey matter). The results
of MRI of the spinal cord are well correlated with the clin-
ical impairment and might be a good surrogate marker.
A comprehensive analysis of MRI parameters in very
large cohorts of ALS patients might reveal a radiological
surrogate marker for use in clinical trials. Several points
should be considered for large scale studies: in 2010, the
first Neuroimaging Symposium in ALS (NiALS) had the
aim of establishing consensus about the various applica-
tions of MRI to the study of ALS and the possibility of mul-
ticentre collaboration. Consensus criteria for the main MRI
sequences (VBM, DTI, fMRI and spectroscopy) and the
main clinical dataset were established [144]. The aim of this
consensus was to lead large multicentre and longitudinal
studies in imaging research or therapeutic trials [144]. <In
our days, studies might better assess the most recent dis-
covers in ALS such as genetic parameters (especially
C9ORF72 expansion), the knowledge in cognitive and be-
havioural impairments even if the patients do not fulfil cri-
teria for frontotemporal dementia [145]. There is still a
need for longitudinal studies especially in presymptomatic
and early phase of the disease [145]. Following this multi-
centre aim, a very recent study showed in 253 patients and
189 controls from eight international ALS specialised
centre more widespread white matter tract change pooling
the analyses than in single-centre analysis and reached esti-
mation of neuropathological changes [146].
Conclusion
The MRI biomarkers appear to be well correlated with
disease severity, duration and progression and are more
sensitive in the brain and spinal cord motor regions. The
built of MRI biomarkers is limited by the clinical various
phenotypes but also by the lack of large and longitudinal
studies. To date large cohorts with multicentre studies
using a standardized MRI protocol are needed.
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